Editas Medicine (EDIT) Misses Q2 EPS by 12c

Editas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.82), $0.12 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $510 thousand versus the consensus estimate of $4.78 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank
• BNP Paribas Exane Upgrades Novonesis A/S (NSISB:DC) to Neutral